Kromann Reumert assisted the Managers in connection with an ABB in Zealand Pharma

Kromann Reumert has assisted the Joint Global Coordinators and Joint Bookrunners, and the Co-Managers in connection with the directed issue and private placement of approximately 2.68 million new ordinary shares in Zealand Pharma A/S giving gross proceeds of approximately DKK 657 million.
Yesterday, Zealand Pharma A/S ("Zealand") announced the launch of a private placement of up to approximately 2.68 million new ordinary shares, at a price to be determined through an accelerated book-building process. The private placement was completed today and has been priced at DKK 245 per share. The accelerated book-building generated gross proceeds of approximately DKK 657 million.

Zealand intends to use the net proceeds to help fund commercialization and pre-launch activities for Zealand's late stage programs, accelerate development of the clinical pipeline, continued support for Zealand’s peptide platform, and for general corporate purposes.

Kromann Reumert has assisted Goldman Sachs International, Jefferies International Limited and Danske Bank A/S who acted as Joint Global Coordinators and Joint Bookrunners, and Needham & Company and Nordea Danmark, Filial af Nordea Bank Abp, Finland who acted as Co-Managers in connection with the accelerated book-building. 

About Zealand 

Zealand (Nasdaq: ZEAL) is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA).